EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia

Bettina Röder, Hannah Fahnenstiel, Simon Schäfer, Bettina Budeus iD, Maria Dampmann iD, Melanie Eichhorn, Sieglinde Angermüller, Claudia Brost, Thomas H Winkler, Marc Seifert, Lars Nitschke iD

EMBO Reports · 2023

DOI: 10.15252/embr.202256420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Reports, 2023. Verfasst von Bettina Röder und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5 + B cells. BCR signaling is regulated by the inhibitory co‐receptor Siglec‐G and Siglec‐G‐deficient mice have an enlarged CD5 + B1a cell population. Here, we determine how Siglec‐G expression influences the severity of CLL. Our results show that Siglec‐G deficiency leads to earlier onset and more severe course of the CLL‐like disease in the murine Eμ‐TCL1 model. In contrast, mice overexpressing Siglec‐G on the B cell surface are almost completely protected from developing CLL‐like disease. Furthermore, we observe a downmodulation of the human ortholog Siglec‐10 from the surface of human CLL cells. These results demonstrate a critical role for Siglec‐G in disease progression in mice, and suggest that a similar mechanism for Siglec‐10 in human CLL may exist.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellMiceAnimalsHumansSialic Acid Binding Immunoglobulin-like LectinsMice, TransgenicProto-Oncogene ProteinsB-LymphocytesReceptors, Antigen, B-Cell

Stichwörter der Autor:innen

BCR signalingCLLSiglec-10Siglec-G overexpressing miceSiglecs

Substanzen

Sialic Acid Binding Immunoglobulin-like LectinsProto-Oncogene ProteinsReceptors, Antigen, B-Cell

Autor:innen und Institutionen

  • Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
  • Medical Faculty, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.

ORCID-Profile: Bettina Budeus, Maria Dampmann, Lars Nitschke

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Röder, B., Fahnenstiel, H., Schäfer, S., Budeus, B., Dampmann, M., Eichhorn, M., Angermüller, S., Brost, C., Winkler, T. H., Seifert, M., & Nitschke, L. (2023). The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia. EMBO Reports. https://doi.org/10.15252/embr.202256420

Vancouver

Röder B, Fahnenstiel H, Schäfer S, Budeus B, Dampmann M, Eichhorn M, et al. The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia. EMBO Reports. 2023. doi:10.15252/embr.202256420

BibTeX
@article{Rder2023,
  author = {Röder, Bettina and Fahnenstiel, Hannah and Schäfer, Simon and Budeus, Bettina and Dampmann, Maria and Eichhorn, Melanie and Angermüller, Sieglinde and Brost, Claudia and Winkler, Thomas H and Seifert, Marc and Nitschke, Lars},
  title = {The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia},
  journal = {EMBO Reports},
  year = {2023},
  doi = {10.15252/embr.202256420}
}
Kostenlos starten →